Observational analysis shows HLA class I staining impacts recurrence risk in adenoid cystic carcinoma, suggesting its prognostic role.
Key Points
Patients with analogous HLA class I staining in tumor and stroma had fewer recurrences, indicating a strong prognostic indicator.
Statistically significant differences were observed in recurrence rates between patients with high HLA class I staining versus those with lower levels.
Assessment involved immunohistochemical staining of HLA class I, CD4, CD8, and FOXP3 in 72 AdCC biopsy samples between 2000 and 2014.
Findings highlight the involvement of HLA class I in recurrence risk, emphasizing its role as a potential prognostic biomarker.